A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia

• Published in: Acta medica Iranica Vol. 53; no. 6; pp. 337 - 345
• Main Authors: Khodaie-Ardakani, Mohammad-Reza, Khosravi, Mohsen, Zarinfard, Razieh, Nejati, Somayeh, Mohsenian, Ali, Tabrizi, Mina, Akhondzadeh, Shahin
• Format: Journal Article
• Language: English
• Published: Iran Tehran University of Medical Sciences 2015
• Subjects: Adult; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - therapeutic use; Depression - drug therapy; Double-Blind Method; Drug Therapy, Combination; Estrogen; Humans; Male; Men; Psychiatric Status Rating Scales; Raloxifene; Raloxifene Hydrochloride - administration & dosage; Raloxifene Hydrochloride - therapeutic use; Risperidone - administration & dosage; Risperidone - therapeutic use; Schizophrenia; Schizophrenia - drug therapy; Treatment Outcome; Young Adult
• ISSN: 0044-6025; 1735-9694

Selective estrogen receptor modulators (SERMs) such as raloxifene have already shown beneficial effects on negative, positive and general psychopathology symptoms in postmenopausal women with schizophrenia. The purpose of the present investigation was to assess the efficacy of raloxifene as an adjuvant agent in the treatment of men with chronic schizophrenia in an 8-week double-blind and placebo-controlled trial. In a randomized, double-blind and placebo-controlled study, forty-six male patients diagnosed with schizophrenia (DSM-IV-TR), were randomized to either raloxifene (120 mg/day) or placebo in addition to risperidone (6 mg/day) for eight weeks. The assessment was performed using the positive and negative symptom scale (PANSS) at baseline, and at weeks 2, 4, 6 and 8. Extrapyramidal symptom rating scale (ESRS) at baseline, weeks 1, 2, 4, 6, 8 and Hamilton depression rating scale (HDRS) at baseline and week 8 were also used to assess extrapyramidal symptoms and depression simultaneously. Forty-two patients completed the trial. The raloxifene group showed significantly greater improvement on the negative subscale (P<0.001), the general psychopathology subscale (P=0.002) and total PANSS score (P<0.001) in comparison to the placebo group at the endpoint. There was no significant difference in the reduction of positive symptoms score between the two group (P=0.525). Extrapyramidal symptom rating scale and Hamilton depression rating scale and frequency of other adverse effects were comparable between two groups.This study indicates raloxifene as a potential adjunctive treatment strategy for chronic schizophrenia in men.